PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb
Phase 1
Completed
- Conditions
- Osteoarthritis Thumbs
- Interventions
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00743587
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation
Phase 2
Withdrawn
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00741884
Arthroscopic Surgical Outcome Study In Subjects With Rotator Cuff Tears
Completed
- Conditions
- Rotator CuffArthroscopic Surgery
- Interventions
- Other: Observational study of the surgical outcome
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 162
- Registration Number
- NCT00739947
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸The Core Institute, Sun City, Arizona, United States
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00739934
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis
Phase 2
Completed
- Conditions
- Interstitial CystitisPainful Bladder Syndrome
- Interventions
- Drug: placebo for PD 0299685Drug: PD 0299685 at 15mg BIDDrug: PD 0299685 at 30mg BID
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 161
- Registration Number
- NCT00739739
- Locations
- 🇩🇪
Pfizer Investigational Site, Muenchen, Germany
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
Phase 3
Withdrawn
- Conditions
- Generalized Anxiety Disorder
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00738738
- Locations
- 🇺🇸
Pfizer Investigational Site, Prairie Village, Kansas, United States
A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2009-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT00736528
- Locations
- 🇺🇸
Pfizer Investigational Site, Gainesville, Florida, United States
Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Interventions
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00735904
- Locations
- 🇺🇦
Pfizer Investigational Site, Lviv, Ukraine
Macugen Observational Study
Terminated
- Conditions
- Vascular Endothelial Growth FactorMacular Degeneration
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00735943
- Locations
- 🇮🇳
Pfizer Investigational Site, Jaipur, Rajasthan, India
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
Phase 3
Terminated
- Conditions
- Generalized Anxiety Disorder
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 468
- Registration Number
- NCT00735267
- Locations
- 🇺🇸
Pfizer Investigational Site, Waukesha, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath